Angiotensin-Converting Enzyme Inhibitors for Stroke Prevention

Angiotensin converting enzyme inhibitors.

The purpose of this brief review is to separate the characteristic properties and side effects attributable to the pharmacology of the whole class of angiotensin converting enzyme (ACE) inhibitors from those attributable to the chemical structure and kinetics of each particular ACE inhibitor. The former would be predictable and probably similar for all agents and, therefore, would be expected t...

Angiotensin-converting enzyme inhibitors.

ACE inhibitors have achieved widespread usage in the treatment of cardiovascular and renal disease. ACE inhibitors alter the balance between the vasoconstrictive, salt-retentive, and hypertrophic properties of angiotensin II (Ang II) and the vasodilatory and natriuretic properties of bradykinin and alter the metabolism of a number of other vasoactive substances. ACE inhibitors differ in the che...

Angiotensin-converting enzyme inhibitors for stroke prevention: is there HOPE for PROGRESS After LIFE?

In the 1990s, it was established that increasing blood pressure (BP) is a causal risk factor for stroke and that lowering BP by any major class of antihypertensive medication reduces the risk of first-ever stroke.1 In 2000 and 2001, it was established from the Heart Outcomes Prevention Evaluation (HOPE) trial and particularly the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) ...

Angiotensin Converting Enzyme in Sarcoidosis

Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention.

We investigated whether protection from coronary heart disease (CHD) and stroke conferred by angiotensin-converting enzyme inhibitors (ACEIs) and calcium channel blockers (CCBs) in hypertensive or high-risk patients may be explained by the specific drug regimen. We extracted summary statistics regarding CHD and stroke from 28 outcome trials that compared either ACEIs or CCBs with diuretics, bet...